Accessibility Menu
Kalaris Therapeutics logo

Kalaris Therapeutics(NASDAQ) KLRS

Current Price$4.01
Market Cap$96.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-65%
5 Year-99%
1 Year+58%
1 Month-8%
Kalaris Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.072026-07-22
Kalaris Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.56%USD 4.822026-07-15
1 month-7.5%USD 4.402026-06-22
3 month-33.28%USD 6.102026-04-23
Year to date-51.78%USD 8.442025-12-31
1 year+58.37%USD 2.572025-07-22
3 year-95.03%USD 81.882023-07-21
5 year-99.06%USD 431.252021-07-23
Since inception-64.78%USD 11.472025-03-19

Kalaris Therapeutics Financials at a Glance

Market Cap

$96.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$44.10M

EPS (TTM)

-$2.14

P/E Ratio

-1.90

Dividend

$0.00

Beta (Volatility)

1.30 (Average)

Price

$4.01

Volume

498

Open

$4.00

Previous Close

$4.07

Daily Range

$4.00 - $4.08

52-Week Range

$2.14 - $11.88

Estimated Earnings Date

Aug 12, 2026

KLRS News

Foolcom-Featured.png

Kalaris Reports Loss Cash at 88 Million

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kalaris Therapeutics

Kalaris develops cell therapies for people with weak immune systems. Its main drug aims to treat serious eye diseases. The company helps patients who face life-threatening viral infections or vision loss.

What’s in the Kalaris Toolbox?

  • TH103 (Lead Drug): A protein-based therapy for eye diseases like age-related macular degeneration; 0% of revenue as of June 2025.
  • Pipeline Expansion: Research into treatments for diabetic eye disease and retinal vein blockage; 0% of revenue.
  • Licensing Agreements: Exclusive rights to technology from University of California, San Diego; 0% of revenue.
  • Outsourced Development: Uses third-party firms for drug manufacturing and clinical trials; 0% of revenue.

Growth Moves: Kalaris on the Map

  • Completed a merger with AlloVir in March 2025, gaining $102.1 million in cash.
  • Launched first clinical trial for TH103 in June 2024; first patient treated in August 2024.
  • Signed a new office lease in Berkeley Heights, New Jersey, in 2025, expanding operations.
  • Secured exclusive technology license from University of California, San Diego for anti-VEGF drugs.
  • Entered a royalty agreement with Samsara BioCapital for future product sales.

Why Kalaris Catches the Eye

Kalaris focuses on a single, innovative drug for eye diseases. It relies on partnerships for technology and manufacturing. The company’s outsourced model keeps its team small and operations flexible.

Five Things You Need to Know

  • No revenue as of Q2 2025; all activities are research-focused.
  • Operating loss was $12 million in Q2 2025, down 192.7% from Q2 2024.
  • Cash and equivalents reached $88.4 million as of June 30, 2025.
  • R&D expenses rose to $8.4 million in Q2 2025, up $5.2 million year-over-year.
  • Company will need more funding after Q4 2026 to continue operations.

Bottom Line

Kalaris is a small biotech firm focused on new eye disease treatments. It remains pre-revenue, with growth driven by research and recent merger activity.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

20

CEO

Andrew Oxtoby, MBA

Website

www.kalaristx.com

Headquarters

Berkeley Heights, NJ 07922, US

KLRS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-72.78%

Return on Capital

-57.50%

Return on Assets

-40.16%

Earnings Yield

-52.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$96.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

23.79M

Volume

498

Avg. Volume

267.16K

Financials (TTM)

Gross Profit

-$20.00K

Operating Income

-$47.63M

EBITDA

-$44.08M

Operating Cash Flow

-$48.89M

Capital Expenditure

-$200.00K

Free Cash Flow

-$49.09M

Cash & ST Invst.

$97.22M

Total Debt

$1.41M

Kalaris Therapeutics Performance Analysis

Kalaris Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Kalaris Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Kalaris Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -50.62-19.6%
20232023-12-31USD -42.09-16.9%
20242024-12-31USD -51.7723.0%
20252025-12-31USD -2.85-94.5%
Kalaris Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3075.8%
Q32025-09-30-4.9%
Q42025-12-3131.3%
Q12026-03-31-4.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$10.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$96.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.84M

N/A

Employees

20

N/A

Net Income

-$10.86M

-6.5%

EBITDA

-$10.85M

-23.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$97.22M

-3.7%

Total Debt

$1.41M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.09M

N/A

Short Term Debt

$317.00K

N/A

Return on Assets

-40.16%

N/A

Return on Invested Capital

-46.82%

N/A

Free Cash Flow

-$13.35M

-79.4%

Operating Cash Flow

-$13.35M

-79.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IFRXInflaRx N.V.
$1.78-1.11%
IMAImageneBio Inc
$5.63-5.70%
CNTXContext Therapeutics Inc.
$0.60-2.18%
CNTBConnect Biopharma Holdings Limited
$2.22+0.95%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.90-0.28%
AALAmerican Airlines Group
$13.65-0.08%
TQQQProShares Trust - ProShares UltraPro Qqq
$65.57-0.07%
TAT&T
$22.83-0.01%

Questions About KLRS

What is the current price of Kalaris Therapeutics?

Kalaris Therapeutics is trading at $4.01 per share.

What is the 52-week range for Kalaris Therapeutics?

Over the past 52 weeks, Kalaris Therapeutics has traded between $2.14 and $11.88.

How much debt does Kalaris Therapeutics have?

As of the most recent reporting period, Kalaris Therapeutics reported total debt of $1.41M.

How much cash does Kalaris Therapeutics have on hand?

Kalaris Therapeutics reported $34.43M in cash and cash equivalents in its most recent financial results.

What is Kalaris Therapeutics’s dividend yield?

Kalaris Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services